Featured Videos
Kill TB and Hepatitis B in one application. (LTC Mall).
PMI's Health-Tec[TM] Surface Disinfectant now kills both TB and Hepatitis B (HBV) in one easy application. This product is alcohol-free and has a pleasant lemon fragrance. Its nonstaining, non-corrosive formula is safe for use on all types of surfaces. Health-Tec is EPA registered and meets
CIRCLE 62 ON READER SERVICE CARD
In addition, make sure to read these articles:
- New Data Support Hepsera's Long-Term...
- Gilead Announces Long-Term Safety and Efficacy...
- Gilead Sciences' Hepatitis B Drug Hepsera Approved...
- DPC's Hepatitis B Antibody Assays Approved by FDA.
- Protection Against Hepatitis B.
- Hepatitis B antibody carriers should be deferred.
- Hepatitis B surface antigen.
- Orthotopic liver transplantation from...
- The risk and cost of hepatitis B exposure in...
- UK advisory board calls for screening liver donors...
- Is your hepatitis B vaccine really protecting you?
- Dragon Announces Acquisition of Hepatitis B...
- OSHA unveils AIDS, hepatitis B protection rules.
- I thought I was immune to hepatitis B.
- Lab groups criticize OSHA rules for AIDS,...
Business Editors/Health/Medical Writers BERLIN--(BUSINESS WIRE)--April 15, 2004 Results of Largest Controlled Clinical Trial in Hepatitis B "e" Antigen-negative Patients; Resistance Analysis and Post-seroconversion Data Presented ......
BOSTON -- Data Show Increasing Serologic, Virologic and Biochemical Response Over 144 Weeks in Treatment-Naive Hepatitis B "e" Antigen-Positive Patients Gilead Sciences (Nasdaq:GILD) today announced ......
Business Editors/Health/Medical Writers FOSTER CITY, Calif.--(BUSINESS WIRE)--March 11, 2003 Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission granted Marketing Authorisation for Hepsera(TM) ......
Business Editors & Health/Medical Writers LOS ANGELES--(BW HealthWire)--July 31, 2002 Diagnostic Products Corporation (NYSE:DP) recently received FDA approval for the IMMULITE(R) and IMMULITE(R) 2000 hepatitis ......
One in 20 Americans will be infected with Hepatitis B at some point in their lives. While sex is the most common way of ......
A recent study indicates that donors who have antibodies to hepatitis B Core antigen (anti-HBc) but are free of hepatitis B surface antigen (HBsAg) may ......
The improved Genetic Systems HBsAg EIA 3.0 Screening Assay is intended for screening blood and blood products for transfusion or for further manufacture into plasma ......
Livers from donors who are seronegative for the hepatitis B virus (HBV) can harbor and transmit HBV infection to recipients, researchers at Shinshu University School ......
Despite the best precautions, a blood collection tube shatters in the lab, lacerating a technologist's fingertip. At bedside, an errant needle jabs a phlebotomist's palm....
A government advisory board has recommended that potential liver transplant donors in Britain be screened for hepatitis B core antibody. The UK Department of Health ......
These blood bankers were surprised to discover that too many of their employees failed to seroconvert following vaccination for HBV. Improper administration wa the culprit....
Business Editors VANCOUVER, British Columbia--(BUSINESS WIRE)--June 8, 2001 Dragon Pharmaceuticals Inc. ("Dragon") is pleased to announce that it has acquired the rights and technology relating ......
The Occupational Safety and Health Administration has released a performance-oriented regulatory approach to protecting a wide range of American workers from the viruses causing AIDS, ......
I thought I was immune to hepatitis B Concern about AIDS in laboratory conversations and journals eclipses the danger of hepatitis B, which is far ......
Lab groups criticize OSHA rules for AIDS, hepatitis B protection Having been deluged by written industry comments and public testimony, the Occupational Safety and Health ......
Email
Digg It
del.icio.us
Related Resources
Press Releases
- New Data Support Hepsera's Long-Term Efficacy against Chronic Hepatitis B.
- 96-Week Data Show Hepsera Reduces Liver Damage and Improves Liver Function in More Than 70 Percent of Patients with Hepatitis B ``E'' Antigen-Negative Disease.
- Gilead Announces Long-Term Safety and Efficacy Data, Through 144 Weeks, for Hepsera in Patients With Chronic Hepatitis B.
Business Resources
Sponsored Links
Site Map | Contact Us | FAQs | About Us | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy
Media Kit
Copyright © 1999 - 2009 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.
© Copyright 2009 The Gale Group, Inc. All rights reserved.
© Copyright © 2002 Medquest Communications, LLC
You may not repost, republish, reproduce, package and/or redistribute the content of this page,
in whole or in part, without the written permission of the copyright holder.
© Copyright © 2002 Medquest Communications, LLC
You may not repost, republish, reproduce, package and/or redistribute the content of this page,
in whole or in part, without the written permission of the copyright holder.
Get In-Depth Company Information from Hoover's | Buy a D&B Credit Report | What is in Your Company's D&B Credit Report?
Online Business Database | Online Business Information | Sales and Marketing Solutions | Business Mailing Lists | Company Profiles
Online Business Database | Online Business Information | Sales and Marketing Solutions | Business Mailing Lists | Company Profiles
Information and opinions on AllBusiness.com solely represent the thoughts and opinions of the authors and are not endorsed by, or reflect the beliefs of,
AllBusiness.com, its parent company D&B, and its affiliates.
AllBusiness.com, its parent company D&B, and its affiliates.
